Discover · The Research Behind It

Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis — Cortese et al., Lancet Psychiatry 2018

Last checked

  • Free
  • Worldwide
  • Research paper
  • Reading
  • Online
Published in
Lancet Psychiatry, 2018
Evidence
Strong
Cost
Free.

What is this paper about?

Pooled 133 double-blind trials of seven ADHD medicines. Over about 12 weeks, all seven reduced clinician-rated ADHD symptoms in children and adolescents compared with placebo (methylphenidate SMD −0.78, 95% CI −0.93 to −0.62), and four of the five tested in adults did (amphetamines SMD −0.79, −0.99 to −0.58). Weighing benefit against side-effects, the authors favoured methylphenidate for children and amphetamines for adults as first choices for short-term treatment.

Why is it in the directory?

Backs up the ADHD practitioner directories and organisations in chapter 09 (CHADD, ADDA, AADPA, ADHD UK) and the ADHD books and webinars in chapter 10 that explain medication choices: a specialist assessment opens the door to medicines with well-tested short-term benefit.

Is it free to read?

Systematic review and network meta-analysis — 133 double-blind randomised trials (10,068 children and adolescents, 8,131 adults in the main analysis). Strong evidence. Lancet Psychiatry 2018;5(9):727–738. DOI 10.1016/S2215-0366(18)30269-4. Free full text in PubMed Central (PMC6109107) — open access, CC BY 4.0.

About the paper

Authors
Cortese S, Adamo N, Del Giovane C, et al.
Published in
Lancet Psychiatry 2018;5(9):727–738
Kind of study
Systematic review and network meta-analysis — 133 double-blind randomised trials (10,068 children and adolescents, 8,131 adults in the main analysis)
Strength of evidence
Strong — a consensus report, guideline or large body of trials points the same way
Free to read
CC BY 4.0

Good to know

  • Trials were short (about 12 weeks), with too few data to judge effects at 6–12 months, and the authors rated certainty low or very low for many comparisons.

Where it sits in the directory

Listed under “Neurodiversity — ADHD, Autism, Dyslexia, Dyspraxia, Dyscalculia & Tics” in chapter 17 of the directory, The Research Behind It, with 12 other listings in the same category.

See every listing in “Neurodiversity”

Similar listings

Also in the directory, with why each one is here.

Browse all 280 in The Research Behind It

This page sums up the listing in Notbroken’s own words, from the provider’s own pages; Notbroken does not run it. A listing is not a recommendation, and Notbroken hasn’t tested the service. The details were last checked against the paper and its listing on 25 October 2026. Page first published 7 November 2026. Services, prices and opening hours change, so check with the provider before you rely on them. General information, not medical, legal or financial advice. How these pages work · Run this service? Ask for a change.